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Recent studies have reported that low serum vitamin D levels are associated with a variety
of diseases, including cardiovascular disease and in particular ischemic heart disease (IHD).
Possible mechanisms underlying this association include increased inflammation, renin-
angiotensin system upregulation, insulin resistance, altered lipid metabolism, and altered
vascular smooth muscle growth and function that lead to hypertension, diabetes,
dyslipidemia and atherosclerosis.[1][2]
However, few longitudinal studies have explored the association between vitamin D levels
and incident IHD. A nested case-control study of male health care professionals found an
approximately doubled risk of incident myocardial infarction associated with lower vitamin
D levels.[3] Other studies have identified trends between vitamin D levels and incident
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myocardial infarction but no statistically significant associations, [4][5][6] at least in part
due to small sample sizes or short follow-up.
The association between vitamin D levels and recurrent IHD has been studied even less
frequently. A cohort study among patients referred for coronary angiography for suspected
coronary artery disease found a statistically significant association between low vitamin D
levels and risk of cardiovascular mortality.[7] A cohort study among patients with a history
of IHD found no significant association between vitamin D levels and risk of secondary
cardiovascular disease including IHD, ischemic stroke, or other cardiovascular disease.[8]
No study has specifically tested the population-based relation between vitamin D levels and
ischemic heart disease among patients with prior cardiovascular disease. In the current
study, we hypothesized that an inverse association exists between vitamin D level and risk
of IHD would be detected in patients with established cardiovascular disease.
We studied a randomly selected, population-based sample of participants in the Canadian
Nova Scotia Health Survey 1995 (NSHS95) who underwent plasma vitamin D
quantification, consented for linkage of their NSHS95 data and subsequent hospitalization or
death data, and had a prior history of cardiovascular disease – IHD, peripheral vascular
disease, or stroke. To identify these conditions, the following International Classification of
Disease (ICD) codes were included: ICD-9 codes V12.5, V45.81, V49.7x, 250.70,
410-414.xx, 415.05, 430-432, 433-435.xx, 440.xx, 441-442.xx, 443.21, 444.xx, 447.xx,
459.9, 593.81, 707.xx, 785.4; or ICD-10 codes E11.5, E10.5, E13.5, E14.5, G45.xx, L98.4,
L97, N28.0, R02, T82.3, Z86.7, Z89.x, Z95.x, 120-125.xx, 160-166.xx, 167.0, 170-174.x,
177.x, 179.2, 199. The design of and data collection for NSHS95 has been described
elsewhere. [9]
25-hydroxyvitamin D (25(OH)D)quantification of serum is the established method of
determining a patient’s vitamin D status.[10] and was measured with the Diasorin
radioimmunoassay method (Stillwater, MN). [11]
Data for IHD events during the 10-year period beginning with a subject’s baseline NSHS95
interview date were provided by the provincial health care registry (hospitalization data) and
Statistics Canada (mortality data, including deaths outside of a hospital). Time to event is
days from NSHS enrollment to IHD event.
Cox regression analyses were performed to evaluate the association between vitamin D level
and IHD events. Covariates in the analyses included season during which plasma was
collected (for vitamin D quantification), age, and cigarette smoking. The analyses were sex-
stratified. Diabetes, hypertension, obesity, and cholesterol were not included as covariates
because they are hypothesized to be in the causal pathway.
In the NSHS95 database of 1844 patients, 244 subjects met our selection criteria.
25(OH)D level was not transformed given its normal distribution as ascertained during
exploratory analysis. 25(OH)D level was divided into three categories for analysis: <15 ng/
mL, 15 to <30 ng/mL, and ≥30 ng/mL. The 30 ng/mL cutoff distinguishes between vitamin
D sufficiency and insufficiency or deficiency.[12][13] A 25(OH)D level above this cutoff is
considered optimal for several health outcomes.[14][15] 25(OH)D levels below this cutoff
are associated with elevated parathyroid hormone(PTH) levels, [16] indicating vitamin D
insufficiency. Although several different cutoffs have been used to distinguish vitamin D
insufficiency and deficiency, 15 ng/mL has been used in multiple studies.[17][3][18]
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13 subjects (5.3%) had vitamin D levels of <15 ng/mL, 140 (57.4%) had levels of 15 to <30
ng/mL, and 91 (37.3%) had levels of ≥30 ng/mL. The subjects’ characteristics are detailed
in Table 1.
114 IHD events occurred during the 10-year follow-up. The figure below show the predicted
Cox regression equations for IHD events according to vitamin D level. In men and women
combined, levels of <30 ng/mL were associated with a hazard ratio of 1.33 (p=.172) for IHD
events compared to levels ≥30 ng/mL. Levels of <15 ng/mL were associated with a hazard
ratio of 2.30 (p=.035) for IHD events compared to levels ≥30 ng/mL (see Figures 1a and
1b).
Our study’s objective was to expand on the thus far limited literature exploring the
association between vitamin D levels and incident or recurrent IHD. We have shown that
among patients with prior cardiovascular disease (including IHD, peripheral vascular
disease, or stroke), marked vitamin D deficiency is associated with an increased risk of IHD
events.
Growing evidence indicates that low vitamin D levels may underlie established
cardiovascular risk factors, perhaps making it in and of itself a cardiovascular risk factor.
Early hypotheses relating vitamin D and IHD stemmed from ecological studies showing
increased IHD incidence or mortality at increased latitude,[19][20] during winter months
[21][22][23], and lower altitude [24] – presumably due to decreased sun exposure and thus
lower vitamin D levels. Indeed, two case-control studies found lower vitamin D levels
among myocardial infarction patients versus controls, with the greatest differences existing
according to season. [25][26]
Specific mechanisms underlying the vitamin D--IHD association have since been explored.
The pathophysiology initially became evident in studies of end-stage renal disease patients.
[27][28] This population’s high IHD burden has been attributed to decreased production of
the active metabolite 1,25-dihydroxyvitamin D (calcitriol) as well as consequent secondary
hyperparathyroidism, both of which lead to atherosclerosis via altered lipoprotein
metabolism and altered vascular smooth muscle growth and function.[1] Low vitamin D
levels may also lead to increased vessel calcification via increased PTH,[1] which would
help explain associations even in non-renal failure populations between low vitamin D
levels and more extensive vascular calcification[29] including incident coronary artery
calcification.[30]
Additional mechanisms have been elucidated. Inflammation and hypertension are both risk
factors for IHD. Low vitamin D levels lead to increased inflammation via increased TNF-α
and IL-6[31] and decreased IL-10.[32] Low vitamin D levels result in upregulation of the
renin-angiotensin system, increasing blood pressure.[2] In fact, low vitamin D levels are
associated with hypertension[33][34][35][18] and vitamin D supplementation has been
shown to decrease systolic blood pressure.[36] Low vitamin D levels are also associated
with other IHD risk factors, including diabetes, obesity, and dyslipidemia.[33][34][18]
Mechanisms underlying these associations include increased insulin resistance and altered
lipid metabolism leading to decreased high-density lipids and increased very low-density
lipids.[1]
It is important to understand how the association found in our study could influence clinical
practice. Once the association is confirmed in larger, more diverse populations, the effect of
vitamin D supplementation on IHD in cardiovascular disease patients should be explored. A
recent meta-analysis of randomized controlled trials involving various patient populations
found that vitamin D supplementation caused decreased total mortality.[37] In cohort
studies, dialysis patients receiving vitamin D supplementation have had decreased mortality
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from cardiovascular disease, including IHD;[38][39] the caveat being that dialysis patients
receive a different vitamin D formulation compared to that typically given to the non-renal
failure population. Therefore, the potential for vitamin D to provide health benefits, and
specifically to reduce the incidence of IHD events in cardiovascular disease patients, may
exist.
Limitations of this study include its observational design and its geographically limited
population. Not all NSHS survey participants underwent vitamin D quantification or
consented for linkage of their survey and subsequent hospitalization or death data,
introducing further selection bias. Also, this analysis relies on medical records in which
ICD-9/10 coding may not always be accurate; however, obtaining data from a universal
healthcare system for the general population is more representative and complete than other
methods. It is also conceivable that vitamin D status simply reflects outdoor physical
activity, making it a surrogate marker for exercise rather than an independent risk factor for
IHD.
The authors of this manuscript have certified that they comply with the Principles of Ethical
Publishing in the International Journal of Cardiology.[40]
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Table 1
Baseline Characteristics of the Patients According to Vitamin D Level
Characteristic
Vitamin D Level
<15 ng/mL 15 to <30 ng/mL >=30 ng/mL p-value
Age 72.1 ± 11.0 65.6 ± 14.5 66.2 ± 15.4 0.315
% Female 53.8% 47.9% 37.4% 0.228
% Smokers 23.1% 27.9% 26.4% 0.919
% Diabetic 23.1% 10.0% 13.2% 0.340
Systolic Blood Pressure (mmHg) 137.1 ± 17.0 134.5 ± 18.0 138.3 ± 20.8 0.331
Body Mass Index (kg/m2) 26.5 ± 6.3 28.1 ± 6.0 27.4 ± 5.6 0.520
Cholesterol (total:HDL) 4.7 ± 1.6 5.1 ± 1.5 5.1 ± 1.4 0.514
% Previous IHD 69.2% 55.7% 62.6% 0.434
% Previous stroke 15.4% 17.1% 15.4% 0.936
% Previous PVD 41.7% 45.7% 34.1% 0.215
Season (quarter of plasma collection) 0.492
 January 1 – March 31 23.1% 11.4% 6.6% 0.146
 April 1 – June 30 53.8% 53.6% 50.6% 0.900
 July 1 – September 30 7.7% 16.4% 33.0% *0.005
 October 1 – December 31 15.4% 18.6% 9.9% 0.201
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